These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22009334)

  • 21. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.
    Nauck MA; Duran S; Kim D; Johns D; Northrup J; Festa A; Brodows R; Trautmann M
    Diabetologia; 2007 Feb; 50(2):259-67. PubMed ID: 17160407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.
    Iltz JL; Baker DE; Setter SM; Keith Campbell R
    Clin Ther; 2006 May; 28(5):652-65. PubMed ID: 16861088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes.
    Rabøl R; Boushel R; Almdal T; Hansen CN; Ploug T; Haugaard SB; Prats C; Madsbad S; Dela F
    Diabetes Obes Metab; 2010 Sep; 12(9):806-14. PubMed ID: 20649633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.
    Diabetes Care; 1998 Jan; 21(1):87-92. PubMed ID: 9538975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle.
    Boushel R; Gnaiger E; Schjerling P; Skovbro M; Kraunsøe R; Dela F
    Diabetologia; 2007 Apr; 50(4):790-6. PubMed ID: 17334651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Pancreas Tonic (an ayurvedic herbal supplement) in type 2 diabetes mellitus.
    Hsia SH; Bazargan M; Davidson MB
    Metabolism; 2004 Sep; 53(9):1166-73. PubMed ID: 15334379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study.
    Gerstein HC; Yale JF; Harris SB; Issa M; Stewart JA; Dempsey E
    Diabet Med; 2006 Jul; 23(7):736-42. PubMed ID: 16842477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.
    Abbasi F; Chu JW; McLaughlin T; Lamendola C; Leary ET; Reaven GM
    Metabolism; 2004 Feb; 53(2):159-64. PubMed ID: 14767866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
    Hällsten K; Virtanen KA; Lönnqvist F; Sipilä H; Oksanen A; Viljanen T; Rönnemaa T; Viikari J; Knuuti J; Nuutila P
    Diabetes; 2002 Dec; 51(12):3479-85. PubMed ID: 12453903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS; Hershon PM
    Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus.
    Simons WR; Hagan MA
    Pharmacoeconomics; 2010; 28(9):765-80. PubMed ID: 20799756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes.
    Donnelly LA; Doney AS; Hattersley AT; Morris AD; Pearson ER
    Diabet Med; 2006 Feb; 23(2):128-33. PubMed ID: 16433709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin selectively attenuates mitochondrial H2O2 emission without affecting respiratory capacity in skeletal muscle of obese rats.
    Kane DA; Anderson EJ; Price JW; Woodlief TL; Lin CT; Bikman BT; Cortright RN; Neufer PD
    Free Radic Biol Med; 2010 Sep; 49(6):1082-7. PubMed ID: 20600832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
    Gallwitz B; Rosenstock J; Rauch T; Bhattacharya S; Patel S; von Eynatten M; Dugi KA; Woerle HJ
    Lancet; 2012 Aug; 380(9840):475-83. PubMed ID: 22748821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.
    Roden M; Mariz S; Brazzale AR; Pacini G
    J Intern Med; 2009 Apr; 265(4):476-87. PubMed ID: 19298459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
    Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.